BAXTER’S HALLE, GERMANY FACILITY RECOGNIZED BY GERMAN FEDERAL AVIATION OFFICE

Certification as “Known Shipper” saves cost and time in delivery of critical products

Baxter’s Halle, Germany facility has been recognized by the German Federal Aviation Office as a “Known Shipper” in that country. This status helps ensure that products manufactured at and shipped from the facility, which largely supports Baxter BioPharma Solutions’ (BPS) contract manufacturing business, are protected from unauthorized access and not required to pass any further security inspection on the way to customers.

Germany’s Known Shipper program is a comprehensive set of mandates that applies to transporting cargo by air. Under the current regulations, all indirect air carriers in Germany — entities that arrange air transportation shipments — are required to establish “known shipper programs”. Only known shippers are authorized to place freight in passenger aircraft; all others must transport freight on cargo aircraft. This limits the types of flights on which shipments can be placed and greatly limits options for cost-effective and timely transportation, something Baxter can avoid thanks to its recent certification.

“We take seriously our commitment to helping patients,” added Dr. Burkhard Wichert. “This recognition in Germany, as well as our status as an Authorized Economic Operator, level F, is another international recognition of our efforts to secure our supply chain and support patients and customers worldwide.”

With more than 50 years of experience, Baxter’s Halle facility has a wide range of capabilities, including commercial-scale production of cytotoxic emulsions, liposomes and suspensions, as well as a nanoparticle suite equipped with a high pressure homogenizer. The site is equipped with barrier isolator technology and is one of the most advanced facilities for cytotoxic contract manufacturing in the world. In 2013, Baxter announced that it would further expand Halle to help meet clients’ growing needs for cytotoxic manufacturing. The Halle facility is part of Baxter’s BioPharma Solutions business, which supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems, and customized support services needed to meet the unique challenges that parental products face.